OncoResponse
SEATTLE, WA · Biotechnology · 12 employees
OncoResponse is a clinical stage, privately held immuno-oncology biotech company developing cancer immunotherapies using clues from the immune systems of elite cancer responders. In a broad strategic alliance with MD Anderson Cancer Center, OncoResponse deploys a proprietary B-cell discovery platform to identify and develop novel therapeutics targeting the tumor microenvironment. The company’s lea
Funding history
- Funding Round — $6.0M — May 2025
- Funding Round — $13.9M — May 2023
- Funding Round — $40.6M — Mar 2021
- Funding Round — $29.5M — Mar 2017
- Funding Round — $16.5M — Oct 2015
Recent signals
- May 06, 2025: Raised $6.0M
- May 12, 2023: Raised $13.9M
- Mar 31, 2021: Raised $40.6M
- Mar 23, 2017: Raised $29.5M
- Oct 15, 2015: Raised $16.5M
See plans & pricing → Track OncoResponse’s funding, hiring, and signals — with verified contacts — on Fundz.